Literature DB >> 29916758

Antigen recognition by single-domain antibodies: structural latitudes and constraints.

Kevin A Henry1, C Roger MacKenzie1,2.   

Abstract

Single-domain antibodies (sdAbs), the autonomous variable domains of heavy chain-only antibodies produced naturally by camelid ungulates and cartilaginous fishes, have evolved to bind antigen using only three complementarity-determining region (CDR) loops rather than the six present in conventional VH:VL antibodies. It has been suggested, based on limited evidence, that sdAbs may adopt paratope structures that predispose them to preferential recognition of recessed protein epitopes, but poor or non-recognition of protuberant epitopes and small molecules. Here, we comprehensively surveyed the evidence in support of this hypothesis. We found some support for a global structural difference in the paratope shapes of sdAbs compared with those of conventional antibodies: sdAb paratopes have smaller molecular surface areas and diameters, more commonly have non-canonical CDR1 and CDR2 structures, and have elongated CDR3 length distributions, but have similar amino acid compositions and are no more extended (interatomic distance measured from CDR base to tip) than conventional antibody paratopes. Comparison of X-ray crystal structures of sdAbs and conventional antibodies in complex with cognate antigens showed that sdAbs and conventional antibodies bury similar solvent-exposed surface areas on proteins and form similar types of non-covalent interactions, although these are more concentrated in the compact sdAb paratope. Thus, sdAbs likely have privileged access to distinct antigenic regions on proteins, but only owing to their small molecular size and not to general differences in molecular recognition mechanism. The evidence surrounding the purported inability of sdAbs to bind small molecules was less clear. The available data provide a structural framework for understanding the evolutionary emergence and function of autonomous heavy chain-only antibodies.

Entities:  

Keywords:  VHH; VNAR; antibody:antigen interaction; epitope; molecular recognition; paratope; single-domain antibody

Mesh:

Substances:

Year:  2018        PMID: 29916758      PMCID: PMC6260137          DOI: 10.1080/19420862.2018.1489633

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  125 in total

1.  A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops.

Authors:  K Decanniere; A Desmyter; M Lauwereys; M A Ghahroudi; S Muyldermans; L Wyns
Journal:  Structure       Date:  1999-04-15       Impact factor: 5.006

2.  Lateral recognition of a dye hapten by a llama VHH domain.

Authors:  S Spinelli; M Tegoni; L Frenken; C van Vliet; C Cambillau
Journal:  J Mol Biol       Date:  2001-08-03       Impact factor: 5.469

Review 3.  Nanobodies as Probes for Protein Dynamics in Vitro and in Cells.

Authors:  Oleg Y Dmitriev; Svetlana Lutsenko; Serge Muyldermans
Journal:  J Biol Chem       Date:  2015-12-16       Impact factor: 5.157

4.  Computational characterization of B-cell epitopes.

Authors:  Nimrod D Rubinstein; Itay Mayrose; Dan Halperin; Daniel Yekutieli; Jonathan M Gershoni; Tal Pupko
Journal:  Mol Immunol       Date:  2007-11-26       Impact factor: 4.407

5.  Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.

Authors:  M Lauwereys; M Arbabi Ghahroudi; A Desmyter; J Kinne; W Hölzer; E De Genst; L Wyns; S Muyldermans
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

6.  Crystal structure of a SLC11 (NRAMP) transporter reveals the basis for transition-metal ion transport.

Authors:  Ines A Ehrnstorfer; Eric R Geertsma; Els Pardon; Jan Steyaert; Raimund Dutzler
Journal:  Nat Struct Mol Biol       Date:  2014-10-19       Impact factor: 15.369

Review 7.  Antibody recognition of carbohydrate epitopes†.

Authors:  Omid Haji-Ghassemi; Ryan J Blackler; N Martin Young; Stephen V Evans
Journal:  Glycobiology       Date:  2015-06-01       Impact factor: 4.313

8.  Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications.

Authors:  Mohamed El Khattabi; Hendrik Adams; Erik Heezius; Pim Hermans; Frank Detmers; Bram Maassen; Peter van der Ley; Jan Tommassen; Theo Verrips; Jord Stam
Journal:  Clin Vaccine Immunol       Date:  2006-08-23

9.  i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.

Authors:  Katherine Griffiths; Olan Dolezal; Benjamin Cao; Susan K Nilsson; Heng B See; Kevin D G Pfleger; Michael Roche; Paul R Gorry; Andrew Pow; Katerina Viduka; Kevin Lim; Bernadine G C Lu; Denison H C Chang; Thomas Murray-Rust; Marc Kvansakul; Matthew A Perugini; Con Dogovski; Marcel Doerflinger; Yuan Zhang; Kathy Parisi; Joanne L Casey; Stewart D Nuttall; Michael Foley
Journal:  J Biol Chem       Date:  2016-04-01       Impact factor: 5.157

10.  Activation and allosteric modulation of a muscarinic acetylcholine receptor.

Authors:  Andrew C Kruse; Aaron M Ring; Aashish Manglik; Jianxin Hu; Kelly Hu; Katrin Eitel; Harald Hübner; Els Pardon; Celine Valant; Patrick M Sexton; Arthur Christopoulos; Christian C Felder; Peter Gmeiner; Jan Steyaert; William I Weis; K Christopher Garcia; Jürgen Wess; Brian K Kobilka
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

View more
  19 in total

1.  Genetic removal of the CH1 exon leads to the production of hypofunctional heavy chain-only IgG2a in rats.

Authors:  Zhenrong Li; Ming Zhang; Shunan Zheng; Yu Song; Xueqian Cheng; Di Yu; Lijuan Du; Liming Ren; Haitang Han; Yaofeng Zhao
Journal:  Transgenic Res       Date:  2020-02-20       Impact factor: 2.788

2.  Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct.

Authors:  Kevin A Henry; Henk van Faassen; Doreen Harcus; Anne Marcil; Jennifer J Hill; Serge Muyldermans; C Roger MacKenzie
Journal:  Immunogenetics       Date:  2019-01-18       Impact factor: 2.846

3.  Coevolved Canonical Loops Conformations of Single-Domain Antibodies: A Tale of Three Pockets Playing Musical Chairs.

Authors:  Francis Gaudreault; Christopher R Corbeil; Enrico O Purisima; Traian Sulea
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

4.  Generation of synthetic nanobodies against delicate proteins.

Authors:  Iwan Zimmermann; Pascal Egloff; Cedric A J Hutter; Benedikt T Kuhn; Philipp Bräuer; Simon Newstead; Roger J P Dawson; Eric R Geertsma; Markus A Seeger
Journal:  Nat Protoc       Date:  2020-04-08       Impact factor: 13.491

Review 5.  Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.

Authors:  Nairo Brilhante-da-Silva; Rosa Maria de Oliveira Sousa; Andrelisse Arruda; Eliza Lima Dos Santos; Anna Carolina Machado Marinho; Rodrigo Guerino Stabeli; Carla Freire Celedonio Fernandes; Soraya Dos Santos Pereira
Journal:  Mol Diagn Ther       Date:  2021-06-19       Impact factor: 4.074

6.  Probing the Kinetic and Thermodynamic Fingerprints of Anti-EGF Nanobodies by Surface Plasmon Resonance.

Authors:  Salvador Guardiola; Monica Varese; Marta Taulés; Mireia Díaz-Lobo; Jesús García; Ernest Giralt
Journal:  Pharmaceuticals (Basel)       Date:  2020-06-26

7.  Structure of a VHH isolated from a naïve phage display library.

Authors:  Brandy White; Ian Huh; Cory L Brooks
Journal:  BMC Res Notes       Date:  2019-03-19

8.  Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice.

Authors:  Svetlana A Godakova; Anatoly N Noskov; Irina D Vinogradova; Galina A Ugriumova; Andrey I Solovyev; Ilias B Esmagambetov; Amir I Tukhvatulin; Denis Y Logunov; Boris S Naroditsky; Dmitry V Shcheblyakov; Aleksandr L Gintsburg
Journal:  Toxins (Basel)       Date:  2019-08-07       Impact factor: 4.546

Review 9.  Theranostics in immuno-oncology using nanobody derivatives.

Authors:  Quentin Lecocq; Yannick De Vlaeminck; Heleen Hanssens; Matthias D'Huyvetter; Geert Raes; Cleo Goyvaerts; Marleen Keyaerts; Nick Devoogdt; Karine Breckpot
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

Review 10.  Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.

Authors:  Lichen Zhu; Xiaomei Yang; Dani Zhong; Shenxia Xie; Wei Shi; Yangzi Li; Xiaoqiong Hou; Huihui Zhou; Minlong Zhao; Ziqiang Ding; Xinyue Zhao; Fengzhen Mo; Shihua Yin; Aiqun Liu; Xiaoling Lu
Journal:  J Immunol Res       Date:  2020-09-07       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.